COIL:

Multi-timeframe price chart with technical indicators - Penny sterling (GBX)

Coiled Therapeutics plc is a clinical-stage biotechnology company focused on developing precision oncology therapies for patients with hard-to-treat cancers. The company’s core activity is the discovery and development of next-generation medicines targeting validated cancer pathways, with an emphasis on solid tumours that have progressed after standard treatments. Its lead programme, AO-252, is a first-in-class, orally administered, brain-penetrant inhibitor of the TACC3 protein, currently being evaluated in a Phase I clinical trial in the United States for advanced solid tumours, including ovarian and prostate cancer. Coiled Therapeutics also maintains a STAT-6 siRNA programme addressing immunology-related indications such as asthma, fibrosis, eczema, and allergic disease, broadening its reach across oncology and immune-mediated conditions. Operating within the biotechnology segment of the healthcare sector, the company serves global pharmaceutical and clinical research markets by advancing novel small-molecule and RNA-based therapeutics designed to improve treatment options and clinical outcomes for patients. Coiled Therapeutics plc is headquartered in London, United Kingdom.

United Kingdom Healthcare Biotechnology UK Healthcare UK Biotechnology

as of Jul. 21, 2026

Stock Data